CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)

SEC fundamentals · as filed in 10-Q FY2026, period ended Jun 30, 2026 · updated Oct 6, 2026

Verified against EDGAR
Total Assets
$9.4M
Stockholders' Equity
$8.7M
Cash & Equivalents
$8.7M
Long-Term Debt
—

as filed in 10-Q FY2026, period ended Jun 30, 2026 · View filings on EDGAR ↗

In its 10-Q for the period ended Jun 30, 2026, CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. reported revenue of $0, net income of -$1.5M, and total assets of $9.4M. Every figure below is taken directly from CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s SEC filings: each links to the source document on EDGAR.

Revenue trend

Revenue · FY2016–FY2025 · as reported

$19.2M-$8.6M-$36.3M
FY2016FY2019FY2022FY2025
Revenue$6,000Net income-$6.0M
FY2016 revenue
$0
FY2025 revenue
$6,000

Revenue and net income by fiscal year

As reported in each year’s annual filing · USD

Fiscal yearRevenueNet income
FY2025$6,000-$6.0M
FY2024$11,000-$5.5M
FY2023$9,000-$5.3M
FY2022$88,600-$10.1M
FY2021$87,754$19.2M
FY2020$164,500-$36.3M
FY2019$165,500-$8.5M
FY2018$124,400-$13.7M
FY2017$4,800-$2.7M
FY2016$0-$766,072

Recent SEC filings

Filed by the registrant · newest first · insider forms and holder schedules not included

FormFiledSource
8-KSep 25, 2026on EDGAR ↗
8-KAug 31, 2026on EDGAR ↗
10-QAug 7, 2026on EDGAR ↗
DEF 14AJul 14, 2026on EDGAR ↗
8-KJul 2, 2026on EDGAR ↗
S-1Jun 25, 2026on EDGAR ↗
10-QMay 8, 2026on EDGAR ↗
10-K/AApr 24, 2026on EDGAR ↗
10-KMar 20, 2026on EDGAR ↗
8-KDec 31, 2025on EDGAR ↗

All filings on EDGAR ↗

Balance Sheet

as of Jun 30, 2026 · 10-Q

Total Assets$9.4Msource ↗
Stockholders’ Equity$8.7Msource ↗
Cash & Equivalents$8.7Msource ↗
Long-Term Debt—source ↗

Income Statement

10-Q (quarterly) · period ended Jun 30, 2026

Revenue$0source ↗
Net Income-$1.5Msource ↗
Operating Income-$1.6Msource ↗
Gross Profit$0source ↗
Cost of Revenue$0source ↗
R&D Expense$459,200source ↗

Per Share & Cash Flow

10-Q (quarterly) · period ended Jun 30, 2026

EPS (diluted)$-0.41source ↗
EPS (basic)—source ↗
Shares Outstanding6.6Msource ↗
Cash from Operations-$1.5Msource ↗
Cash from Financing$4.5Msource ↗
Cash from Investing$0source ↗

Restatement history

Point-in-time

9 of 355 annual fact-keys were materially restated between filings: what CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. first reported differed from what it later filed. We keep every vintage of every annual figure, each keyed to its EDGAR accession.

See each original-vs-restated value, and query any company as of any past date, with the point-in-time API.

Deeper fundamentals

A free API key reaches CELZ’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.

Programmatic access

Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.

These fundamentals, as filed
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/CELZ

MCP tool: get_sec_fundamentals ticker=CELZ

The same figures as they were known on any past date
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/CELZ/as-of/YYYY-MM-DD

MCP tool: get_asof_fundamentals ticker=CELZ as_of=YYYY-MM-DD

Fiscal-year trajectory: revenue, margins, free cash flow
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/fundamentals/CELZ/history

MCP tool: get_fundamentals_history ticker=CELZ

Leverage, liquidity, margin and return ratios
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
https://api.distillmarkets.com/api/v1/sec/financial-health/CELZ

MCP tool: get_financial_health ticker=CELZ

Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.